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Abstract  
Anastrozole has been shown to prevent breast cancer in postmenopausal women at 
high risk of the disease, but has been associated with substantial accelerated loss of 
bone mineral density (BMD) and increased fractures. Here, we investigate the effect 
of risedronate on BMD after 5 years of follow-up in the IBIS-II prevention trial. 1410 
women were enrolled in the bone sub-study and stratified into three strata according 
to the lowest baseline T-score at spine or femoral neck. The objective was to 
compare the effect of oral risedronate (35mg weekly) versus placebo in osteopenic 
women in stratum II who were randomised to anastrozole in the main study. 258 
osteopenic, postmenopausal women at high risk of developing breast cancer for 
whom baseline and follow-up bone mineral density measurements were available. 5-
year mean BMD change at the lumbar spine for osteopenic women randomised to 
anastrozole and risedronate was -0.4% compared to -4.2% for those not on 
risedronate (P<0.0001) but not significantly different between risedronate users and 
non-users at the hip (P=0.2). 5-year mean PINP change was -20% for those 
randomised to anastrozole and risedronate compared to 3% for those not on 
risedronate but on anastrozole (P<0.0001). Our results confirm the bone loss 
associated with the use of anastrozole and show that anastrozole-induced BMD loss 
in the spine can be controlled with risedronate treatment. However, our results 
suggest that weekly oral risedronate is unable to completely prevent anastrozole 
induced bone loss at the hip. 
 
Keywords: osteopenia, bone mineral density, anastrozole, risedronate, bone 
marker, breast cancer risk 
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Introduction 
Postmenopausal women are at high risk of developing osteoporosis (low mineral 
bone density (BMD)) due to decreasing levels of estrogen. Early postmenopausal 
BMD loss is estimated to be between 1 to 3% per year at the spine and 1 to 2% per 
year at the hip [1]. Bisphosphonates, which increase BMD by inhibiting osteoclast-
mediated bone resorption [2, 3], can prevent bone loss in postmenopausal women. 
 
Aromatase inhibitors (AIs) have become the standard adjuvant treatment option for 
postmenopausal women with hormone receptor positive breast cancer. The risk of 
BMD loss, and therefore fractures, in this patient population is increased due to AIs 
ability to suppress estrogen levels by inhibiting the conversion of androgens to 
estrogens by the aromatase enzyme in soft tissues, especially fat. The majority of 
studies investigating the effect of AIs on BMD have been performed in 
postmenopausal women with early breast cancer receiving adjuvant tamoxifen as a 
comparison group, which has been shown to have a beneficial effect on BMD [4, 5]. 
Most studies demonstrating a beneficial effect of bisphosphonates on the bone have 
been performed in breast cancer patients receiving an AI [6-10], and little is known 
about the effect of bisphosphonates in healthy postmenopausal women who are at 
risk of developing the disease. 
 
The IBIS-II trial compared anastrozole with placebo in postmenopausal women at 
high risk of developing breast cancer and found a significant 53% reduction in breast 
cancer with anastrozole [11]. Due to these results, anastrazole has been 
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recommended by the National Institute for Health and Care Excellence (NICE) for 
the prevention of breast cancer for postmenopausal women with family history. We 
have previously reported that 3 years of oral risedronate can prevent BMD loss in 
osteopenic and osteoporotic postmenopausal women who were receiving 
anastrozole [12]. Furthermore, this was the first study to report the effect of 
anastrozole on BMD loss in healthy postmenopausal women in a placebo-controlled 
trial. The decrease in BMD and the increase in bone turnover markers with 
aromatase inhibition would be expected to be associated with an increase in fracture 
risk, although our study wasn’t powered to test for this. Here, we update the IBIS-II 
bone sub-study results by adding in the bone turnover marker N-Terminal Propeptide 
of Type I Collagen (PINP) and report in detail on the effect of risedronate on BMD in 
postmenopausal women with osteopenia. 
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Materials and Methods 
1. Study design and participants 
We have previously described the study design and eligibility of the IBIS-II bone sub-
study [12]. Entry criteria were designed to include women aged 45–60 years who 
had a relative risk of breast cancer that was at least two times higher than in the 
general population, those aged 60–70 years who had a risk that was at least 1.5 
times higher, and those aged 40–44 years who had a risk that was four times higher. 
The IBIS-II bone sub-study enrolled 1410 women and they were stratified into three 
groups according to the lowest baseline T-score at either femoral neck or lumbar 
spine (Figure 1).  
 
 
Women who were osteopenic (-2.5≤ T-score<-1.0) were entered into stratum II and 
were additionally randomised to receive oral risedronate (35mg per week) or 
matching placebo (N=500). For this analysis only women from stratum II and those 
who did not develop breast cancer or died were included. All women were advised, 
but not required, to take vitamin D and calcium supplements. Exclusion criteria for 
the bone sub-study included previous bilateral hip fractures, women with any type of 
metabolic bone disease, and women who have regularly taken medication affecting 
bone metabolism within the past 12 months prior to study entry. Breast cancer 
development was the primary endpoint of the IBIS-II trial and women were excluded 
from the current analysis if they developed breast cancer at any point during the 
active treatment period. The trial was approved by the UK North West Multicentre 
Research Ethics Committee and was done in accordance with the Declaration of 
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Helsinki, under the principles of good clinical practice. Participants provided written 
informed consent. 
 
2. Assessments 
BMD was assessed by follow-up DXA scans at the lumbar spine and hip at 1, 3 and 
5 years. BMD measurements at the femoral neck are more variable as it relies on a 
smaller region of the bone than total hip. Therefore, we report here BMD 
measurements for the total hip. A final DXA scan at 7 years (two years after 
treatment cessation) was also performed, but these results are not reported here. T-
scores were calculated using either the GE-Lunar [13] or Hologic [14] manufacturer’s 
reference age-specific ranges for the lumbar spine (L1 to L4) and the NHANES III 
reference range for the femoral neck region [15]. For quality assurance, all baseline 
and follow-up DXA scans were reviewed centrally by two clinical scientists with 
expertise in bone densitometry (GMB and RP). Women in stratum II of the bone sub-
study were randomised to receive oral risedronate or matching placebo using 
randomly chosen blocks of size six, eight, or ten to maintain balance. Compliance in 
stratum II was determined full if women took their allocated risedronate at least 80% 
over 5 years of follow-up (at least 208 weeks over 5 years). Women who had a BMD 
loss of 6 percent or more at the 12 month’s visit were furthermore required to have a 
safety DXA scan at 24 months of follow-up. Similarly, those with a BMD loss of over 
ten percent at 36 months had a safety scan at 48 months, and those with a BMD 
loss of over 16% at the 60 month’s visit, had an interval scan at 72 months. Further 
details on assessments in the bone sub-study can be found in our previous 
publication [12].  
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Blood samples were taking in the non-fasting state and the serum separated and 
stored at -70 C. The total N-Terminal Propeptide of Type I Collagen (PINP) was 
measured using the Cobas e411 automated immunoassay (Roche Diagnostics, 
Penzburg, Germany). The precision of PINP was assessed by measuring a serum 
quality control sample daily. The coefficient of variation was calculated and 
expressed as a percentage. The mean (SD) PINP concentration of this QC was 47.7 
(2.4) ng/ml and the coefficient of variance was 5%. 
 
 
3. Statistical analysis 
The primary objective of this analysis was to compare the effect of risedronate 
versus placebo on the BMD change between baseline and 5 years at both the 
lumbar spine and total hip for women in stratum II who were randomised to 
anastrozole. Secondary objectives included comparison of baseline and randomised 
treatment effects on PINP measurements at study entry and 12 and 60 months of 
follow-up. 
 
All results are expressed as percent mean BMD changes (with corresponding 95% 
confidence intervals) at the lumbar spine and total hip between baseline and 5 years. 
BMD changes and differences between treatment groups were assessed using 
paired t-tests for normal distribution. Pearson’s correlation coefficient analysis was 
used to examine the relationship between and the values of BMD and PINP. Adverse 
events were compared with relative risks. P-values were two-sided, based on normal 
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approximation and all confidence intervals were at the 95% level.  Analyses were 
performed using STATA version 13.1 (College Station, Texas USA). 
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Results 
1410 postmenopausal women were entered into the bone sub-study (Figure 1). 258 
women in stratum II had baseline and subsequent follow-up BMD measurements up 
to 5 years and were included in this analysis. Baseline characteristics for women in 
this analysis are shown in Table 1.  
 
 
Overall, compliance to risedronate in stratum II was very good and only 26 women 
(4%) were identified as not fully compliant over 5 years of follow-up. Sensitivity 
analyses excluding these women did not alter the results presented here (data not 
shown). The main reason of missing DXA data was due to withdrawal from the main 
IBIS-II study due to anastrozole related adverse events. The most common reported 
adverse event were joint-related symptoms, such as arthralgia, joint stiffness, and 
joint pain. Most of these events were reported within the first 2 years since 
randomisation. Other reasons for non-compliance in the bone sub-study were the 
development of breast cancer (primary endpoint of the main trial), other cancers, and 
death. Women who developed breast cancer or those who died were not included in 
this analysis. All women were advised to take calcium and vitamin D supplements 
but no specific doses were specified or required as per protocol. 68% of women took 
these supplements during the 5-year treatment period. We did not observe any 
difference in BMD changes between those on supplements compared to those who 
did not take them, irrespective of treatment allocation. 
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127 osteopenic women who were randomised to anastrozole in the main trial had all 
BMD measurements available between baseline and 5 years of follow-up. Of these 
68 were additionally randomised to risedronate (versus 59 to placebo). We observed 
a significant difference in mean % BMD change for those on risedronate (-0.4%) at 
the lumbar spine after 5 years of follow-up compared to those not receiving 
risedronate (-4.2%) (Difference: -3.8% (95% CI -5.5 to -2.3); P<0.0001) (Figure 2).  
 
 
Osteopenic women receiving anastrozole and placebo showed a linear decrease in 
lumbar spine BMD with time over 5 years of follow-up whereas those receiving 
anastrozole and risedronate showed an initial BMD increase at the lumbar spine, 
which stabilised within 5 years of follow-up (Figure 2). At the total hip, risedronate did 
not prevent anastrozole-induced bone loss (Figure 2). Women receiving risedronate 
had a mean BMD decrease at the total hip of -2.5% compared to a mean decrease of 
-3.8% for those not receiving risedronate (Difference: -1.3% (95% CI -3.2 to 0.5); 
P=0.2). The BMD decrease observed at the total hip with anastrozole and 
risedronate (-2.5%) was very similar to that among osteopenic women not receiving 
any treatment (-2.7%, Figure 2). 
 
Osteopenic women who were randomised to placebo in the main trial and 
additionally to risedronate (N=74) showed a mean BMD increase of 3.9% (95% CI 
2.2 to 5.6) at the lumbar spine over 5 years of follow-up (Figure 2). A highly 
significant difference (P=0.0001) was observed compared to those receiving placebo 
(N=57) who maintained their mean BMD at the lumbar spine over 5 years of follow-
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up (-0.1% (95% CI -1.3 to 1.0)). A similar but less striking picture was seen at the 
total hip. Women receiving risedronate (N=72) showed an initial increase in mean 
BMD after 3 years (1.8% (95% CI 1.0 to 2.7), which declined to 0.9% (95% CI -0.3 to 
2.1) after 5 years. However, these BMD changes were significantly different in those 
receiving placebo only (N=55) (-2.7% (95% CI -3.4 to -2.0); P<0.0001) (Figure 2). 
Overall, most rapid bone loss occurred in year 1, as defined by BMD loss of more 
than 6% since baseline, occurred in year 1 (N=17). These women had to stop with 
the trial and were given a bisphosphonate. 1 women had rapid bone loss at year 5, 
which was defined as BMD change of more than 16% since baseline.  
 
 
Women receiving anastrozole and risedronate had a mean PINP decrease of 27% at 
12 months and 20% at 60 months as compared to a mean increase of 16% at 12 
months and 3% at 60 months for those not receiving risedronate (Figure 3).  
 
 
 
 
Women receiving risedronate only had a mean PINP decrease of 48% at 12 months 
and 30% at 60 months as compared to a mean decrease of 6% at 12 months and 
4% at 60 months for those not receiving risedronate (Figure 3). All differences were 
highly statistically significant (P<0.001). The 12-month change in PINP in the 
risedronate group was correlated with 12-month change in lumbar spine BMD (r=-
0.33, P=0.0003) and in the total hip (r=-0.21, P=0.03). The 60-month change in PINP 
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in the risedronate group was correlated with 60-month change in lumbar spine BMD 
(r=-0.26, P=0.008) and in the total hip (r=-0.29, P=0.003). There were no significant 
correlations between change in PINP and BMD in the groups not receiving 
risedronate. 
 
Pre-defined side effects, such as abdominal pain, bloating, diarrhoea, and 
constipation, reported during 5 years of follow-up were statistically not significantly 
different between risedronate treatment allocations (data not shown). We also did not 
observe any osteonecrosis of the jaw during 5 years of risedronate treatment. A total 
of 97 osteopenic women reported fractures in the bone sub-study (Table 2) but no 
significant difference between anastrozole and placebo was observed (RR=0.98 
(95% CI 0.61-1.56); P=0.7). No difference in reported fractures was observed 
between women receiving risedronate compared to those who did not (Table 2).  
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Discussion 
In postmenopausal women with osteopenia, this study showed that weekly oral 
risedronate for 5 years can prevent anastrozole-induced bone loss at the lumbar 
spine, but not the hip. Risedronate was very well tolerated and no serious adverse 
events, such as osteonecrosis of the jaw, were reported during the 5 years on 
treatment. Compliance to risedronate was very good and the exclusion of non-
compliant women had no impact on BMD changes.  
 
Apart from the MAP.3 trial [16], most evidence that AIs have a negative effect on 
BMD come from adjuvant trials in women with early breast cancer [4, 17, 18]. These 
trials have all shown significant BMD loss with an AI, but have in common that the 
comparator was tamoxifen, which has been shown to have a beneficial impact on 
bone [9, 19]. Similarly, all other reports that have investigated the effect of a 
bisphosphonate on BMD in women taking anastrozole come from treatment trials [8, 
20-23]. Greenspan et al. found that weekly risedronate improved BMD and 
decreased bone turnover markers in postmenopausal women with hormone receptor 
positive breast cancer who were given an AI for 2 years. Although this was a small 
study and the follow-up period was relatively short, they demonstrated that 
measurements of bone markers (C-telopeptide crosslinks type I collagen (CTX) and 
N-Terminal Propeptide of Type I Collagen (PINP)) can predict BMD changes. We 
observed correlations between 12-month change in PINP and BMD that were very 
similar.  
 
One key finding of our study was the observation that long-term risedronate intake 
wasn’t preventing bone loss at the total hip, although it was effective at the lumbar 
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spine. We did not find any evidence that poor compliance with risedronate was 
responsible for this. Risedronate might not be sufficiently potent in the presence of 
long-term anastrozole used, which is supported by a lesser effect at 60 months on 
the PINP changes. Furthermore, our current results differ from previous analysis at 
the three year follow-up [12]. Risedronate clearly is sufficiently potent to prevent hip 
bone loss in women not receiving anastrozole after 60 months, a finding in keeping 
with a clinical trial over 60 months in 220 women with osteoporosis [24]. We did not 
observe any reduction in fractures with risedronate irrespective of main 
randomisation. This is in contrast to adjuvant breast cancer studies, which have 
shown to significantly reduce the incidence of fractures with bisphosphonates, both 
vertebral and non-vertebral fractures [4, 25, 26]. However, these trials have all in 
common that the comparator was tamoxifen, which has been shown to have 
beneficial impact on bone [9, 19, 26]. Our trial was not designed to investigate the 
use of risedronate for the prevention of fractures and they were not our primary 
endpoint. In postmenopausal osteoporosis, the effect of risedronate on non-vertebral 
fracture reduction is about 20% [27]. In the current study, the point estimate of 
reduction in fracture risk was 9% but in order to detect such a change in fracture risk, 
a much larger study would need to be performed.  
 
 
The results from this study in women at risk of developing breast cancer can be 
compared to previous studies of women with breast cancer treated with aromatase 
inhibitors. For example, in the ATAC study [28] the 5-year rate of bone loss at the 
lumbar spine and total hip were 6.1% and 7.2%, considerably greater than in this 
preventive study of 4.2% and 3.8%, respectively. It has been considered that women 
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with breast cancer are particularly susceptible to the development of osteoporosis 
[29]. This is somewhat surprising given that the PINP level was similar in the ATAC 
study and IBIS-II (mean PINP around 55 mcg/L) and the change in PINP was 
between 155 and 20% [30]. 
 
This analysis has several strengths and limitations. Strengths include a good sample 
size (N=258) of women with osteopenia and long-term follow-up of 5 years. The 
population included in this analysis came from a large prevention trial [11] with 
excellent clinical records and detailed follow-up. An additional strength of this study 
is the evaluation of BMD changes and risedronate in a placebo-controlled trial of 
healthy postmenopausal women who are at increased risk of developing breast 
cancer. Our results might be useful for women at increased risk of breast cancer who 
consider taking anastrozole for prevention purposes. 
 
Limitations of our study include the incomplete set of BMD data at 5 years, which 
was mainly due to withdrawal from the main IBIS-II study due to anastrozole related 
side effects. Therefore, our results might not be representative for the whole study 
population. However, when all BMD measurements (incomplete data between 
baseline, 1, 3, and 5 years) were included in a sensitivity analysis, similar results 
were observed. Two types of DXA machines were used to assess BMD changes in 
this study. However, comparisons of BMD changes between Hologic and GE-Lunar 
scanners did not reveal any significant differences. DXA measurement doesn’t take 
into account bone structure and micro-architecture of the bone, which plays an 
important role in determining bone strength [16, 31, 32]. However, it was not possible 
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to assess these structural changes within the remit of the bone sub-study protocol. 
All women had to stop with bone anabolic therapy or selective estrogen replacement 
therapy 12 months before joining the IBIS-II trial. Although we did not collect detailed 
information on medication before the 12 months to trial entry, we do not believe that 
prior intake of these drugs had any impact on BMD changes during the trial. Lastly, 
we were not able to measure a bone resorption marker as the only one that can be 
measured in serum after long-term storage and is reliable is CTX, which needs to be 
measured in a sample obtained fasting. The reason we measured PINP is that 
oestrogen deficiency results in an increase both in resorption and formation markers 
(due to coupling) and bisphosphonates result in a decrease in both types of marker. 
 
 
Conclusion 
 
The IBIS-II results strongly support anastrozole for preventive treatment of high risk 
postmenopausal women [11]. This updated analysis in healthy postmenopausal 
women in a placebo controlled trial confirmed the beneficial effect of risedronate on 
bone loss at the lumbar spine only in osteopenic women receiving anastrozole. We 
found that the use of a bisphosphonate and monitoring of bone density by DXA 
scans can control BMD loss induced at the lumbar spine by anastrozole in the 
preventive setting. However, bone loss at the hip was not completely prevented and 
therefore other more potent bisphosphonates (e.g. alendronate, zoledronic acid) for 
prevention of hip bone loss and fracture need to be investigated in this setting.. 
Risedronate was well tolerated and may provide a therapeutic option to maintain 
skeletal health in women at increased risk of developing breast cancer.  
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Figure legends: 
 
Figure 1: CONSORT diagram of enrolled women and BMD data included in this 
analysis. 
 
Figure 2: Mean % BMD changes at lumbar spine and total hip at each follow-up visit 
for women in stratum II. Numbers below the figures show women at each follow-up 
visit with available DXA scan. 
 
Figure 3: Mean % PINP changes between baseline and 12, 60 months for women in 
stratum II receiving anastrozole (left) or placebo (right) and randomised to either 
risedronate or placebo. Numbers below the figures show women at each follow-up 
visit with available DXA scan. 
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Table 1: Baseline characteristics for osteopenic women according to main and risedronate randomisation. 
  
P/P 
(N=74) 
P/R 
(N=59) 
A/P 
(N=57) 
A/R 
(N=68) 
Age (years), median (IQR) 59.7 (56.8-63.3) 60.8 (57.4-61.4) 60.2 (55.2-65.3) 59.7 (55.9-64.2) 
BMI (kg/m
2
), median (IQR) 26.8 (23.6-32.0) 26.2 (24.5-29.4) 26.3 (23.9-30.7) 26.2 (23.3-26.7) 
Previous HRT use (%) 43.2% 42.4% 45.6% 51.5% 
Never smokers (%)  59.5% 64.4% 61.4% 58.8% 
Lowest baseline T-score at lumbar 
spine or femoral neck, median (IQR) 
-1.34 (-1.78 to -1.11) -1.78 (-2.03 to -1.41) -1.38 (-1.85 to -1.09) -1.73 (-2.10 to -1.33) 
PINP, median (IQR) 54.1 (40.7-69.1) 56.2 (40.7-71.1) 52.4 (42.6-70.4) 54.0 (45.6-67.5) 
Data are median (interquartile range) or percentage (%). Abbreviations: P=Placebo, R=Risedroante, A=Anastrozole, IQR=interquartile range, BMI=body mass index, kg=kilogram, m=meter, 
HRT=hormone replacement therapy, PINP= N-Terminal Propeptide of Type I Collagen 
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Table 2: Number of women reporting fractures according to treatment allocation. 
 
 Anastrozole Placebo OR (95% CI) 
Fractures 50 47 0.98 (0.61-1.56) 
No risedronate 30 29 1.02 (0.57-1.83) 
Risedronate 20 18 0.91 (0.46-1.81) 
Data are numbers or Odds Ratio (OR). Abbreviations: OR=Odds Ratio, CI=Confidence Interval. 
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Highlights 
 
 Results confirm anastrozole induced bone mineral density decrease with anastrozole 
in women at increased risk of developing breast cancer 
 
 Risedronate counterbalances the negative effect of anastrozole induced bone mineral 
density loss at the lumbar spine in osteopenic women 
 
 Long-term intake of risedronate did not prevent bone loss at the total hip in osteopenic 
women 
 
 N-Terminal Propeptide of Type I Collagen (PINP) can predict bone mineral density 
changes 
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